Key result
LVAD therapy with functional improvement is linked to ~6-fold higher cardiomyocyte renewal versus healthy hearts.
Why the study?
Adult human cardiomyocytes have a low baseline regenerative capacity, but whether this regenerative capacity is employed in heart failure has remained controversial.
Does left ventricular assist device (LVAD) support increase cardiomyocyte renewal in patients with advanced heart failure?
Observational (n=52)
Yes
Does left ventricular assist device (LVAD) support increase cardiomyocyte renewal in patients with advanced heart failure?
LVAD unloading in advanced heart failure unmasks a latent potential for cardiomyocyte regeneration, significantly increasing renewal rates.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for LVAD-enhanced cardiomyocyte renewal in advanced HF; does not support practice change.
BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial. METHODS: We determined cardiomyocyte renewal in 52 patients with advanced heart failure, 28 of whom received left ventricular assist device support. We measured the concentration of nuclear bomb test–derived 14 C in cardiomyocyte genomic DNA and performed mathematical modeling to establish cardiomyocyte renewal in heart failure with and without LVAD unloading. RESULTS: We show that cardiomyocyte generation is minimal in end-stage heart failure patients at rates 18 to 50× lower compared with the healthy heart. However, patients receiving left ventricle support device therapy, who showed significant functional and structural cardiac improvement, had a >6-fold increase in cardiomyocyte renewal relative to the healthy heart. CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.
No takes yet. Share an insight, caveat, or question.
Derks et al. (2024) conducted an observational in Advanced heart failure (n=52). Left ventricular assist device (LVAD) support vs. Non-LVAD advanced heart failure was evaluated on Annual cardiomyocyte renewal rate. Patients with advanced heart failure receiving left ventricular assist device therapy who showed functional improvement had a cardiomyocyte renewal rate of 3.1% per year, a >6-fold increase relative to healthy hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: